Lindahl acted as legal advisor to Corline Biomedical
Through the agreement, Imperative Care is given the exclusive right to use CHS™ in all types of neurovascular products given a certain level of compensation. Corline undertakes to supply CHS™-coated products according to defined specifications, but also to assist in further development and market registration of the current product. In addition, Corline will participate in the development of additional CHS™-coated products within the indication area. These products have the potential to generate revenue for Corline of approximately SEK 150 million per year and a total of more than SEK 1 billion.
Lindahl's team consisted of Hugo Norlén and Erika Svensson.
Corline's press release (in Swedish) is available here.
Do you want to know more? Contact:
Hugo Norlén
Partner | AdvokatErika Svensson
Partner | AdvokatCarousel items
-
Cases and transactions
7/13/2026
Lindahl Advises Bokusgruppen AB (publ) on the Acquisition of Pen Store Sthlm AB
Lindahl has advised Bokusgruppen on its acquisition of Pen Store, the leading Nordic retailer of pens and artists' materials serving customers across the EU.
-
News articles
7/7/2026
Lindahl included among Sweden's ten most reputable patent firms for the second consecutive year
For the second consecutive year, Lindahl has been named among Sweden's ten most reputable patent law firms by The Patent Lawyer Magazine – a testament to the firm's strong expertise and long-term commitment in intellectual property law.
-
Portraits
7/3/2026
Jesper on business-oriented legal advice in energy: "It is not enough for the advice to be correct"
Lindahl's energy team is recognised in Legal 500 for combining deep regulatory expertise with broad commercial legal experience – find out how they support clients in a rapidly evolving sector.
-
Knowledge
6/29/2026
The scope of the Swedish FDI Act is expanded – is your business affected?
MCF's new regulation (MCFFS 2026:13) expands the scope of the Swedish FDI Act from 15 July 2026. Is your business affected? Read about the key changes.
-
Read more news and insights?